“TMU BioMed Accelerator” and “BE Health Ventures” joint demo day will be launched online on August 2nd!
For opening remarks, TMU and BE especially invite Chih-Cheng Yeh, general director of the Department of International Cooperation and Science Education, Ministry of Science and Technology, and Chen-li Sun, professor of Science and Technology Division, Taipei Economic and Cultural Office in San Francisco. In addition, there are Chien-Huang Lin, president of Taipei Medical University (TMU) and Arthur Chen, managing partner of BE Health Ventures. They both encourage startups to strengthen international linkage and to be proactive creating more opportunities.
Ever since the year of 2020, the outbreak of pandemic, the “Hospital VC” collaboration between TMU and BE Health Ventures has shown the strength of this innovative combination. It provides access to conduct clinical trials and product verification in the hospital, and with the clinical resources support, it also raises the acceptance rate from the physicians, and therefore accelerates the process, cutting out half-year on average of time consumed, making Taiwan the first choice when planning to expand the Asian market.
12 startups, 6 months accelerating programs.
The 2022 batch of TMUxBE Accelerator Program was launched this February, recruited 12 groups of startups in total, and 5 of them are from oversea, including teams from Taiwan, United States, Canada, Japan, Singapore, Israel. Covering fields ranging from AI disease prediction, smart wearable devices, pathological data analysis platforms, personal precision treatment, etc.
[USA] Dyad Medical Inc.
[Canada] IRegained Inc.
[Japan] CROSS SYNC, Inc.
[Singapore] FathomX Pte Ltd.
[Taiwan] QT Medical, Inc.
[Taiwan] MedicalTek Co., Ltd.
[Taiwan] AcroViz Inc.
[Taiwan] Cancerfree Biotech Ltd.
[Taiwan] Health League Inc.
[Taiwan] Virtual Man Inc.
With access to clinical databases, we provide just what our startups need.
“The most common problem BE sees in the development of a product is that, usually healthcare startups don’t know the decision process of the hospital” Arthur of BE Health Ventures mentioned, who has been dedicated to the healthcare ecosystem for years. In addition to that, Chien-Huang Lin, president of Taipei Medical University (TMU) also resonated with Stanford Biodesign program and started a “Three-Hospital Consultative Committee” in TMU, which gathered decision-makers of the Taipei Medical University Hospital, Wan Fang Hospital and Shuang Ho Hospital to discuss about potential clinical cooperation with startups and clinical field validation.
Besides, to extend to a broader data collection, TMUxBE Accelerator Program is linking with TMU data office, which has three-hospital’s abundant electronic medical records, research platform connected from 19 countries (over 100 databases), and TMU Office of Human Research, to assist startups in developing their strategy on clinical trials.
“Pandemic, Inflation, and Aging Society” The new healthcare trend under the current chaos.
This time, TMU and BE specially invite worldwide renowned experts to join us in this demo day, including the president of ExploraMed, the chief of sleep surgery at Stanford Medicine, the Intuitive Ventures in Silicon Valley and the Taiwan medical data expert Prof. Yu-Chuan Li, etc., to talk about the coping strategy on rising cost for healthcare system due to the pandemic, inflation, and aging society.
In healthcare Silicon Valley, we use Taiwan as a launchpad into the Asian market.
TMUxBE Accelerator Program was launched in 2020, which provides international market-oriented training courses for startups. The program have mentors from U.S. Stanford Biodesign to share their experience in the industry, also, there are courses related to the U.S. reimbursement to build up the fundamental knowledge towards CMS of the U.S. Federal Government, to reduce developing risks through learning cost effectiveness and to assess the threshold of being covered under payment.
TMUxBE Accelerator Program selects outstanding startups which were incubated by the program, assisting them to expand oversea markets and deliver remarkable achievements, including RDS from France, Neurobit and Dentall from Taiwan, they have all successfully raised more than USD$100 million. Also, Long Good from Taiwan, they already received FDA ClassII approval, and AESOP from Taiwan, they have made their way into the U.S market by completing the verification with Brigham and Women’s Hospital from Harvard Medical School.
The accelerator program leverages the solid industry resources of BE Health Ventures, and clinical data resources of TMU, it provides serial customized training courses, the ecosystem, exposure opportunity and business validation. TMUxBE Accelerator Program plans to build an Asian Silicon Valley of healthcare here in Taiwan, making Taiwan the Gateway to Asia for Healthtech.